Details of the Drug Combination

General Information of Drug Combination (ID: DCYFGJT)

Drug Combination Name
Xanomeline tartrate Trospium
Indication
Disease Entry Status REF
Schizophrenia Phase 1 [1]
Component Drugs Xanomeline tartrate   DMXG5WU Trospium   DMX6RTG
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Xanomeline tartrate
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 2 [2]
Xanomeline tartrate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Muscarinic acetylcholine receptor M1 (CHRM1) TTZ9SOR ACM1_HUMAN Agonist [6]
------------------------------------------------------------------------------------
Indication(s) of Trospium
Disease Entry ICD 11 Status REF
Overactive bladder GC50.0 Approved [3]
Spasm MB47.3 Approved [3]
Neurogenic detrusor overactivity GC01 Phase 1 [4]
Priapism N.A. Investigative [5]
Trospium Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Muscarinic acetylcholine receptor M5 (CHRM5) TTH18TF ACM5_HUMAN Antagonist [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02831231) Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
2 The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action. Pain. 2011 Dec;152(12):2852-60.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7480).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Trospium FDA Label
6 Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
7 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.